Noveris Health Sciences (MYCOF) reported that all resolutions at its September 4, 2026 annual general and special meeting were approved, with 21,697,593 common shares represented, or about 37.06% of shares entitled to vote.
Shareholders set the number of directors at three, with over 99.9% of votes cast in favour. Jason Birmingham, Michael Callas and Peter Field were each elected as directors, receiving approximately 99.98% votes for and 0.02% withheld. HDCPA Professional Corporation was appointed auditor, with 99.98% of votes for. The Amended and Restated Omnibus Long-Term Incentive Plan was approved with 99.89% support, and a special resolution to amend the Articles to change quorum requirements passed with 99.94% of votes for.
Noveris Health Sciences (CSE: NVRS, OTC Pink: MYCOF) plans a non-brokered private placement of convertible debentures for aggregate gross proceeds of up to $500,000, in $1,000 denominations, expected to close on or about August 28, 2026.
The debentures bear 10% annual interest, mature 12 months after closing, and are convertible after four months into units at the greater of $0.05 or the 20-day CSE volume-weighted average price. Each unit includes one common share and one warrant, with warrants exercisable for 24 months at a price determined by the same formula. Noveris intends to use net proceeds for working capital, G&A, and R&D. The offering is subject to CSE approval, carries a four-month-and-one-day hold period, and will not result in a change of control.
Noveris Health Sciences (OTC Pink: MYCOF) announced that the USPTO has issued a Notice of Allowance for U.S. Patent Application No. 18/443,025, covering six claims on aza-substituted psilocin analogs and related pharmaceutical compositions. The examiner distinguished the claimed compounds from prior art based on the R2 substituent, and the application stems from a patent family originating in December 2021.
The Notice of Allowance completes substantive examination but is not yet a granted patent; issuance depends on meeting USPTO requirements and paying issue and publication fees, which Noveris intends to do. The company also signed a work order and provided $146,000 in funding to Applied Pharmaceutical Innovation to restart synthesis and in vitro evaluation of promising psilocybin-related compounds, generate data to guide future R&D decisions, and enable potential rapid GMP scale-up if further clinical development is warranted.
Noveris Health Sciences (OTC Pink: MYCOF) reported that, at the request of CIRO, its management is unaware of any material change in the company’s operations that would explain recent increases in market activity. Noveris is a Canadian life sciences company focused on mental health and therapeutic innovation.
Noveris Health Sciences (CSE: NVRS, OTC Pink: MYCOF) has joined BioAlberta, a not-for-profit association representing Alberta's life sciences community. The company said this membership complements its existing relationship with Applied Pharmaceutical Innovation (API), which supports Noveris on psilocybin product development and related IP opportunities.
According to Noveris, the BioAlberta membership is separate from its API master services agreement and does not create a partnership, commercial agreement, financing arrangement or endorsement by BioAlberta. No securities are being issued and no material financial commitment is associated with the membership.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.